Drug intelligence / Profile preview

Alphavis-T

Development stage
Phase 4
Lead developer
Grevis Pharma
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Alphavis-T is a fixed-dose combination ophthalmic solution developed and marketed by Grevis Pharma for the management of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The formulation contains brimonidine tartrate (0.2%), a selective alpha-2 adrenergic receptor agonist, and timolol maleate (0.5%), a non-selective beta-adrenergic receptor blocker. These components work through complementary mechanisms: timolol reduces the formation of aqueous humor, while brimonidine both decreases aqueous humor production and enhances uveoscleral outflow. This dual action effectively lowers IOP in patients who require more than one medication to achieve target pressure levels. It is administered topically as eye drops twice daily.

Brand names
Alphavis-T
Other names
brimonidine tartrate + timolol maleate eye dropsbrimonidine + timolol
02

Targets

ADRA2A (α2A)ADRB1 (β1)ADRB2 (β2)

Beyond the preview

Go deeper on Alphavis-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphavis-T.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call